Discovery of 4-cyclopropyl-3-(2-((1-cyclopropyl-1H-pyrazol-4-yl) amino) quinazolin-6-yl)-N-(3-(trifluoromethyl) phenyl) benzamides as potent discoidin domain receptor inhibitors for the treatment of idiopathic pulmonary fibrosis

• Main Authors: Qi Wang (Author), Bixi Tang (Author), Dandan Sun (Author), Ying Dong (Author), Yinchun Ji (Author), Huanyu Shi (Author), Liwei Zhou (Author), Yueyue Yang (Author), Menglan Luo (Author), Qian Tan (Author), Lin Chen (Author), Yue Dong (Author), Cong Li (Author), Rongrong Xie (Author), Yi Zang (Author), Jingkang Shen (Author), Bing Xiong (Author), Jia Li (Author), Danqi Chen (Author)
• Format: Book
• Published: Elsevier, 2022-04-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Idiopathic pulmonary fibrosis (IPF) is a chronic fatal lung disease with a median survival time of 3-5 years. Inaccurate diagnosis, limited clinical therapy and high mortality together indicate that the development of effective therapeutics for IPF is an urgent need. In recent years, it was reported...